Portfolio Lab

Dexcom Inc

  • Stock
  • Ticker DXCM
  • ISIN US2521311074
  • Nasdaq

Health care · Medical technology · USA

$79.32 −1.08%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Dexcom Inc since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

DXCMGlobal equities (VT)

$10,000 grew to $43,356. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −66.3% in 11/2025, measured from the peak in 11/2021. The old peak has not been reached again yet.

1-year return
+35.8%
5-year return p.a.
−13.1%
10-year return p.a.
+15.8%
Volatility p.a.
51.5%
Largest decline
−66.3%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue1,1141,0361,1571,2091,2601,1921,3081,345
Gross profit656589689731793750830864
Operating income189134213243323255318327
EBITDA247194276306388322387402
Net income152105180284267200249275
Earnings per share0.380.270.450.700.670.510.640.72
Balance sheet
Total assets6,4856,7527,3277,5006,3406,6336,4556,239
Liabilities4,3824,4854,7544,7743,5943,6763,8343,703
Equity2,1032,2672,5732,7262,7462,9572,6212,535
Cash6069051,1591,8369181,1181,105961
Cash flow
Operating cash flow301184303660294526269326
Capital expenditure-125-87-94-81-102-77-85-53
Free cash flow17797209579192449185273

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2018 at +108.7%, weakest 2024 at −37.3%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
29 Oct 2026$0.72
30 Jul 2026$0.64
30 Apr 2026$0.51
12 Feb 2026$0.67
30 Oct 2025$0.70
30 Jul 2025$0.45
1 May 2025$0.27
18 Feb 2025$0.38
24 Oct 2024$0.34
25 Jul 2024$0.35
25 Apr 2024$0.36
8 Feb 2024$0.61

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€27bn
Market cap in trading currency
$29.6bn
Enterprise value
$28.6bn
P/E
31.2
P/S
5.80
P/B
11.67
EV/Sales
5.61
EV/EBITDA
19.1
Earnings yield
3.2%
FCF yield
3.7%

Results (last four quarters)

Revenue
$5.10bn
Gross profit
$3.24bn
EBITDA
$1.50bn
Net income
$991m
Earnings per share
$2.54
Revenue per share
$13.69
Revenue growth
+11.2%
Earnings growth
−3.1%

Profitability

Gross margin
63.4%
Operating margin
24.0%
Net margin
19.4%
Return on equity
37.7%
Return on assets
15.9%

Balance sheet and cash flow

Cash
$961m
Cash per share
$2.58
Financial debt
–
Debt/equity %
–
Current ratio
1.74
Book value per share
$6.80
Operating cash flow
$1.41bn
Free cash flow
$1.10bn

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
373m
Volume
4.41m
Avg. volume 3 months
4.23m
Relative volume
1.1

Price and technicals

Price
$79.32
1 day
−1.1%
52-week high
$92.34
52-week low
$57.56
Distance to 52-week high
−14.1%
Distance to 52-week low
+37.8%
Distance to 50-day line
−5.5%
Distance to 200-day line
+5.3%
RSI (14)
43
Volatility 1M
44.1%

Performance

1 week
−4.8%
1 month
+1.3%
3 months
−12.9%
6 months
+10.0%
YTD
+19.5%
1 year
+32.8%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has DXCM performed since 11/2016?

$10,000 grew to $43,356 by 20 Nov 2026, which is +15.8% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is DXCM?

Volatility was 51.5% per year, measured on monthly returns. The largest decline from a peak was −66.3%, with the low in 11/2025.

How does DXCM compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, DXCM returned +15.8% at 51.5%. The correlation of monthly returns was 0.29; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Dexcom Inc (DXCM): Return and risk | Portfolio Lab